Three human implants. Ten billion dollars in revenue. And a Pre-IPO fund that stitches them into the same portfolio. MSX's third vintage just added Neuralink and Anduril. The narrative writes itself: artificial intelligence expanding from the human brain to the battlefield. The story is compelling. The financials, however, are not. Logic survives the crash; emotion dissolves.
MSX Pre-IPO III is a fund designed to capture the final private round before public listing. Its strategy: invest in high-growth, narrative-rich companies, hold for 2-3 years, exit via IPO. Neuralink, the brain-computer interface company, has raised over $500 million and is valued at around $80-100 billion in its latest round. Anduril, the defense AI startup, is valued at $250-300 billion, with $10 billion in projected 2025 revenue. The two companies span the extreme ends of AI application: biological integration and autonomous warfare. The fund's thesis is that both are entering their commercialization phase and will soon go public, delivering 3-5x returns.
Let us dissect the technical and financial foundations.
Neuralink's technology is impressive but immature. The N1 chip, with 1,024 channels, has been implanted in three patients. The FDA granted breakthrough device designation, but the company is still in the Investigational Device Exemption phase. No revenue. No path to profitability within the fund's expected holding period. The valuation of $80-100 billion implies a future market cap of $200-300 billion at IPO, assuming no dilution. That is a multiple of infinity on zero revenue. Compare to Synchron, a non-invasive competitor, which has 10 patients and a less risky regulatory path. The market is pricing in a monopoly that does not yet exist.
Anduril is better positioned. Its Lattice platform is deployed in defense contracts. Revenue is real and growing. But the valuation of 14-28x sales is on the high end for a hardware-heavy company. Anduril's customer concentration is extreme: the U.S. Department of Defense. One budget cut or a shift in threat perception could compress multiples. The acquisition of Callum (3D printing) for $1.3-1.4 billion adds integration risk. The 2025 revenue of $10 billion is a projection; actuals may be lower. Precision is the only antidote to chaos.
The fund's narrative is that AI is the ultimate frontier. But frontier investing carries frontier risk. The technical debt in both companies is significant. Neuralink's long-term safety data on electrode degradation and signal attenuation is absent. Anduril's autonomous systems have not been tested in large-scale, multi-domain conflict. The technology works in controlled environments; the real world is uncontrolled.
I have spent years auditing hardware-software integration projects. The gap between a prototype and a production system is where most value is destroyed. Neuralink's surgery robot is elegant, but scaling to thousands of patients requires manufacturing consistency that has not been demonstrated. Anduril's software-defined approach is a threat to incumbents, but incumbents have deep relationships and distribution channels that AI-first companies lack.
Furthermore, the Pre-IPO fund structure entails a lock-in period of 5-7 years. If Neuralink's FDA approval slips by two years, the fund's exit window may close. If Anduril's defense contracts are delayed by budget negotiations, the valuation may reset. The return of 3-5x is based on a smooth path; the market is not smooth.
What do the bulls see? They see the AI narrative accelerating. Neuralink is the only company with a human implant exceeding 1,000 channels. Anduril is the only defense AI company that has built a complete operating system for autonomous warfare. The timing is right: both companies are at the inflection point where technology meets market demand. The fund's dual bet is a hedge: if one fails, the other may succeed. The narrative also attracts capital from limited partners who want exposure to the next wave of AI—both in healthcare and national security. The bulls argue that the valuations are justified by the size of the addressable markets: brain-computer interface is a $100 billion market by 2030, defense AI is a $500 billion market. Even a small share yields enormous returns.
But the bulls ignore the competition. Synchron's non-invasive approach may win on safety. Palantir's deep government ties may crowd out Anduril. The market is not a vacuum; it is a competitive arena. Clarity cuts deeper than noise.
MSX's Pre-IPO III is a bet on narrative, timing, and technical execution. The narratives are strong, the timing is opportunistic, but the execution is unproven. The fund's return hinges on two variables: Neuralink's regulatory clearance and Anduril's contract renewal. Both are binary outcomes. The margin of safety is thin. Investors should ask: what is the technical floor? If the brain chip fails, what is the salvage value? If the defense contracts are not renewed, what is the floor? The data does not support a high confidence call. The only certainty is that logic survives the crash; emotion dissolves. The crash may not come, but preparation is the only hedge.